Grateful for the opportunity to present our work at #EBMT2026 (Oral Session on GVHD Basic & Translational Research).

We focused on tissue-resident memory T cells and their association with steroid-refractory GI GvHD.

#Hematology #GvHD #TranslationalResearch

🩸Brazilian pediatric consensus reviews 3 post-allogeneic #HSCT cell therapies: DLI to amplify GvL, stem cell boost for graft dysfunction, and MSC for refractory #GvHD. 🆓https://doi.org/10.46765/2675-374X.2025v6n1e309
#MedSky #hematology #oncology #oncopediatrics #JBMTCT

The intestinal microbiota as a key modulator of acute graft-versus-host disease - Nature Reviews Cancer In this Review, Paredes et al. discuss preclinical and clinical evidence suggesting that the intestinal microbiome influences outcomes of allogeneic haematopoietic cell transplantation and, in particu...

The #microbiota driven road towards development of personalized therapies for patients receiving allo-HCT, integrating #microbiome profiles with individual risk data #GVHD www.nature.com/articles/s41...

Brazilian New Pediatric Consensus on Acute Graft-versus-Host Disease (aGvHD): Updates on Prophylaxis, MAGIC Staging, & Therapy Algorithms. Corticosteroids remain 1st line; Ruxolitinib is confirmed for refractory cases.
doi.org/10.46765/267...
#PediatricHemOnc #BMT #GvHD #Hematology #MedSky #JBMTCT

Axatilimab Plus Ruxolitinib May Be a Safe Combination Against Newly Diagnosed GVHD - Hematology Advisor Researchers sought to determine whether combining axatilimab and ruxolitinib is a safe strategy among patients with newly diagnosed chronic GVHD.

REVEAL study: Axatilimab + ruxolitinib achieved 69% ORR in R/R #cGvHD. 🩺

60% of patients reported ≥1 Grade 3 TEAE.

20.5% experienced Grade 4.

Findings from #Tandem26 via @astct.bsky.social @cibmtr.bsky.social

Read the review: https://bit.ly/4cyLJ9o

#Hematology #GvHD #MedicalNews

GVHD Alliance | Unite to Raise Awareness of GVHD Support, stories, and resources for the GVHD community—patients, caregivers, clinicians, and advocates.

Graft-vs-host disease is a serious, life-threatening complication affecting up to 1 in 2 patients who undergo a stem cell transplant. My lab is dedicated to eradicating this horrible disease. Today, on #GVHDDay, visit gvhdalliance.org to learn more about #GVHD & raise awareness.

Graft-vs-host disease is a serious complication affecting the lives of up to 1 in 2 patients who undergo a stem cell transplant.

This #GVHDDay, join us to spread the word: learn more about the mission of #GVHDAlliance to empower people with #GVHD: 👉 https://www.gvhdalliance.org/

Proud of this collaborative study, now in print @jclinicalinvest (w/cover) BIOPREVENT is a tree-based #machine learning algorithm using clinical parameters and #Biomarkers to predict chronic #GVHD. A Shiny app is available @NMDP and @CIBMTR

From Tandem last week:
Karen DeMairo (Blood Cancer United) received this year’s Patient Advocate Award, and we loved connecting with her and Meredith Cowden (Meredith A. Cowden Foundation) — two incredible voices for the transplant & GVHD community.

#TandemMeetings #GVHD #PatientAdvocacy

RSV Antibody Levels Tied to Posttransplant Infection Risk After hematopoietic cell transplant, sirolimus use for GVHD prophylaxis is linked to a higher RSV risk, whereas higher serum neutralizing antibody levels are tied to a lower risk within 100 days.

The @jimboonya.bsky.social lab at Fred Hutch found the use of sirolimus #GVHD prophylaxis in allo HCT recipients was linked to a higher risk for RSV infection, whereas higher serum neutralizing antibody levels were linked to a lower risk in the first 100 days post-transplant. https://wb.md/3Zokzua

RSV Antibody Levels Tied to Posttransplant Infection Risk After hematopoietic cell transplant, sirolimus use for GVHD prophylaxis is linked to a higher RSV risk, whereas higher serum neutralizing antibody levels are tied to a lower risk within 100 days.

The @jimboonya.bsky.social lab at Fred Hutch found the use of sirolimus #GVHD prophylaxis in allo HCT recipients was linked to a higher risk for RSV infection, whereas higher serum neutralizing antibody levels were linked to a lower risk in the first 100 days post-transplant. https://wb.md/3Zokzua

New episode of Thrive! 🎧
Episode Five looks at ocular GVHD — why eye symptoms after transplant are often missed and why early recognition matters.

🎧 Apple Podcasts: podcasts.apple.com/us/podcast/t...
▶️ YouTube: youtu.be/-jweNibsxWw

#OcularGVHD #GVHD #StemCellTransplant #Survivorship

#Tandem26 has begun! Come see us at booth # 511.

🧫 Meet the Scientists of Eurofins Viracor
🎙 Be a guest on Transplant Radio™
🎨 Win a painting from world renowned artist, "Scribe" Donald Ross

#Tandem2026 #gvhd #cartcell

🩸 Additional insights on emerging therapies & future directions in Inherited Bone Marrow Failure Syndromes

#Hematology #RareDiseases #IBMFS #InheritedBoneMarrowFailure #BoneMarrowFailure #NGS #Hematopathology #Microbiome #GVHD #StemCellTransplant #HEMEHUB

🩸 Additional insights on long-term complications and surveillance in Inherited Bone Marrow Failure Syndromes

#IBMFS #BoneMarrowFailure #HCT #StemCellTransplant #AvascularNecrosis #GVHD #SquamousCellCarcinoma #Hematology #RareDiseases #HEMEHUB

🩸 Additional insights on HCT challenges in Inherited Bone Marrow Failure Syndromes

#IBMFS #InheritedBoneMarrowFailure #HCT #GVHD #Hematology #HemeOnc #BoneMarrowFailure #ClinicalInsights #MedEd

Does donor age still matter in allogeneic haemopoietic cell transplant?

This week, we summarised a study which investigated whether post-transplant cyclophosphamide (PTCy) attenuates the adverse impact of older unrelated donors.

🔗 MedED summary: bit.ly/4bFaq3u

#Haematology #GVHD #Transplant

💡 Today's question! See the answer and explanation on the next slide.

#Hematology #FanconiAnemia #BMF #HCT #GVHD #BoneMarrowFailure #RareHematology #MedEd #HemeHub

MDADI MDADI

How are new strategies improving prevention and treatment of #GVHD after HCT?

Watch this on-demand activity featuring insights from @DrZackDeFilipp, @hamiltkyb & Dr. Amandeep Salhotra—produced with @peerview.bsky.social #ASH25 #MedEd

🔗 bit.ly/4apt6Un

Isabel Veloso explica diagnóstico de doença do enxerto A cantora Isabel Veloso revelou recentemente que está enfrentando a doença do enxerto, condição que pode surgir em pessoas que passaram por transplantes de órgãos ou medula óssea. O anúncio chamou atenção dos fãs e levantou dúvidas sobre o que significa esse diagnóstico. A doença ocorre quando as células do doador atacam o corpo de [...] The post Isabel Veloso explica diagnóstico de doença do enxerto appeared first on Márcia Piovesan.

BMT InfoNet is offering a professionally facilitated online support group for spouses and partners of adults living with chronic GVHD.

🗓 Begins Jan 6, 2026
💻 Online via Zoom

Pre-register here:
bmtinfonet.org/form/pre-reg...

#SpouseCaregiver #ChronicGVHD #GVHD #CaregiverSupport

🏥 Have a look at the Clinical Case of the Month: Between Immunosuppression and Immune Control: Managing Severe GI-GVHD and Intestinal PTLD After Allogeneic Stem Cell Transplant ⬇️
ebmt.org/ebmt/news/cl...

👥 Submitted by Giulia Losi and Nicola Polverelli

#HCT #GVHD #CellTherapy

Living with chronic GVHD can feel isolating — but support is available.

Adults with chronic graft-versus-host disease are invited to pre-register for our professionally facilitated online support group starting in 2026.

🔗 bmtinfonet.org/form/gvhd-su...

#GVHD #TransplantSurvivor #SupportMatters

Advances in GvHD management presented at ASH 2025 In this interview, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses key advances and developments in graft-versus-host disease (GvHD)...

🎥 Prof. Mohamad Mohty, MD, PhD, in an exclusive interview with VJ HemOnc at #ASH2025, shared #GvHD advances and Xervyteg® (MaaT013) with a 54% one-year survival rate.

👉 Full interview: www.vjhemonc.com/video/uz21rt...
@ash.hematology.org @vjhemonc.bsky.social

Post-Transplantation Cyclophosphamide May Reduce Chronic GVHD Risk Compared With MMF Combining post-transplantation cyclophosphamide with sirolimus and cyclosporine appears to reduce the incidence of cGVHD compared with sirolimus, cyclosporine, and MMF.

Combining post-transplantation cyclophosphamide with sirolimus and cyclosporine appears to reduce the incidence of #cGVHD compared with sirolimus, cyclosporine, and MMF. Published in @ascopost.bsky.social Journal of Clinical Oncology.

https://bit.ly/48VJZnn

#GVHD

Fred Hutch #BMT and #GVHD expert Dr. Geoffrey Hill spoke to Fred Hutch News about the lifesaving strides that have been made in GVHD treatment, and where the research is focused next. Read more: https://bit.ly/48FyccO

Fred Hutch #BMT and #GVHD expert Dr. Geoffrey Hill spoke to Fred Hutch News about the lifesaving strides that have been made in GVHD treatment, and where the research is focused next. Read more: https://bit.ly/48FyccO

Fred Hutch at #ASH25: Catch Dr. Marie Bleakely discuss graft engineering and post-transplantation T cell #immunotherapy strategies for minimizing serious #GVHD and preventing relapse of hematological malignancies. 👉 https://bit.ly/4rEPGP2

Fred Hutch #BMT and #GVHD expert Dr. Geoffrey Hill spoke to Fred Hutch News about the lifesaving strides that have been made in GVHD treatment, and where the research is focused next. Read more: https://bit.ly/48FyccO

Ruxolitinib Superior to Best Available Therapy in Managing Steroid-Refractory Acute GVHD Researchers determined ruxolitinib performed better than best available therapy in the management of a cohort of patients with SR-aGVHD over a 24-month period.

Ruxolitinib performed better than best available therapy in the management of a cohort of patients with SR-aGVHD over a 24-month period. Published in the @ascopost.bsky.social journal Journal of Clinical Oncology.

https://bit.ly/3XEBLuq

#GVHD